Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES OPUS IN CONJUNCTION WITH ACQUISITION OF DREW TECHNOLOGIES
Mandate

VINGE ADVISES OPUS IN CONJUNCTION WITH ACQUISITION OF DREW TECHNOLOGIES

February 13, 2015 Automotive, Mobility and Electrification

Vinge has advised Opus Group in connection with Opus Inspection, Inc.’s acquisition of all shares in Drew Technologies Inc., Michigan USA. Drew is a leading manufacturer of vehicle analysis equipment and diagnostics equipment for the vehicle inspection industry and OEM vehicle industry. The purchase price is USD 30 million (approximately SEK 250 million) plus a possible earn-out of USD 4.4 million (approximately SEK 36.5 million).  The transaction has been financed through a cash payment of USD 25 million (approximately SEK 209 million) and a directed issue in kind to the sellers of USD 5 million (approximately SEK 42 million). The transaction is expected to be completed within a thirty day period.

Vinge’s team consisted of responsible partner Anders Strid and associates Daniel Lennartsson and Frida Bäckergren.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026